Načítá se...
True and false positive rates for different criteria of evaluating statistical evidence from clinical trials
BACKGROUND: Until recently a typical rule that has often been used for the endorsement of new medications by the Food and Drug Administration has been the existence of at least two statistically significant clinical trials favoring the new medication. This rule has consequences for the true positive...
Uloženo v:
| Vydáno v: | BMC Med Res Methodol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6882054/ https://ncbi.nlm.nih.gov/pubmed/31775644 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12874-019-0865-y |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|